Maze Therapeutics, Inc. (MAZE)
| Market Cap | 1.43B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -131.12M |
| Shares Out | 55.25M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,594 |
| Open | 26.47 |
| Previous Close | 26.47 |
| Day's Range | 25.36 - 27.15 |
| 52-Week Range | 7.79 - 53.65 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 68.25 (+164.33%) |
| Earnings Date | May 13, 2026 |
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also deve... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for MAZE stock is "Strong Buy." The 12-month stock price target is $68.25, which is an increase of 164.33% from the latest price.
News
Maze Therapeutics Announces $150 Million Registered Offering
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its co...
MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze...
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829
• Maze Therapeutics stock is among today's weakest performers. What's behind MAZE decline?
Maze Therapeutics Transcript: Study result
Phase II HORIZON data show MZE829 achieved a 36% mean reduction in proteinuria in broad AMKD, with 61.8% reduction in FSGS and 48.6% in non-diabetics. The drug was well-tolerated, and early diabetic data are promising. Plans are underway for a pivotal program.
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated ...
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conferenc...
Maze Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing two key programs: MZE-829 for APOL1-mediated kidney disease, aiming for first-in-class proof of concept with a fully funded phase 2b/3 study, and MZE-782 for PKU and CKD, showing best-in-class early data and planning phase 2 trials. Multiple clinical catalysts are expected this year, supported by strong financials and growing diagnostic infrastructure.
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Key clinical programs are advancing, with MZE829 data expected soon and MZE782 phase 2 studies for PKU and CKD planned this year. The company’s dual-mechanism approach aims to improve outcomes in kidney and metabolic diseases, with a focus on regulatory pathways and patient impact.
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Precision medicines for kidney and metabolic diseases are advancing, with MZE829 phase II data for APOL1 kidney disease expected by end of Q1 2026 and MZE782 phase II for PKU and CKD planned for 2026. Strong capital position supports all key milestones into 2028.
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Major milestones included going public, launching the MZE829 APOL1 kidney disease study, and advancing MZE782. The Horizon trial targets a broad AMKD population, aiming for a 30% proteinuria reduction, with pivotal data expected by Q1 2026. Strategic plans include phase 2b/3 studies and leveraging regulatory advances.
Maze Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Focused on precision medicine for kidney and metabolic diseases, the company is advancing two lead small molecule programs—MZE829 for APOL1-mediated kidney disease and MZE782 for PKU and CKD—toward key phase II milestones in 2026, supported by strong clinical data and recent financing.
Maze Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Recent conference presentations reinforced the genetic and mechanistic understanding of APOL1-mediated kidney disease, with a dual-mechanism inhibitor showing strong preclinical results and a pivotal clinical readout expected in Q1 2026. The pipeline also includes a promising SLC6A19 inhibitor for PKU and CKD.
Maze Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing precision medicines for kidney and metabolic diseases, with pivotal data for its APOL1-mediated kidney disease program expected in Q1 2026. Its pipeline includes promising candidates for both PKU and CKD, supported by strong preclinical and early clinical results.
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to i...
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease
Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease.
San Francisco is making a comeback. So are these stocks from the City by the Bay
CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pati...
Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential
Maze Therapeutics, Inc. MAZE on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19.
Maze Therapeutics Transcript: Study Result
Phase I results for MZE-782 in healthy volunteers showed excellent safety, linear PK, and robust, dose-dependent increases in urinary phenylalanine and glutamine excretion, confirming target engagement. An initial, reversible eGFR dip supports kidney benefit, enabling Phase II trials in PKU and CKD in 2026.
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pat...